Sagent Pharmaceuticals, Inc. 4
4 · Sagent Pharmaceuticals, Inc. · Filed Aug 31, 2016
Insider Transaction Report
Form 4
Harmon J Frank
EVP, Global Operations
Transactions
- Disposition to Issuer
Common Stock
2016-08-29$21.75/sh−8,915$193,901→ 0 total - Disposition to Issuer
Stock Option to Buy
2016-08-29$8.29/sh−18,897$156,656→ 0 totalExercise: $13.46Exp: 2026-03-14→ Common Stock (18,897 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these restricted shares were canceled and converted into the right to receive $21.75 per share, without interest, less any applicable withholding taxes (the "Merger Consideration").
- [F2]Represents the disposition of options, which provided for vesting in four equal installments beginning Mach 14, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $8.29 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration.